ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
TH-302 (evofosfamide) monotherapy exerts anticancer activity in Ewing's sarcoma cells under hypoxia.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Multi-omics exploration of hypoxia in gastric cancer.World journal of surgical oncology · 2026Article
- Hypoxia-driven metastatic progression in synovial sarcoma: insights from SYO-1 and SW982 models.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor hypoxia is a significant factor in cancer progression, metastasis, and therapy resistance, leading to poor patient outcomes. Hypoxia-activated prodrugs (HAPs) are a class of agents that selectively target these hypoxic environments. They remain inactive under normal oxygen conditions but are activated by low oxygen levels. TH-302 (evofosfamide), a nitroimidazole mustard, is a clinically advanced HAP. This study aimed to investigate the effects of TH-302 in three Ewing's sarcoma (ES) cell lines.
methodsTH-302 was assessed for its effects on DNA damage, cell proliferation, cell death, mitochondrial depolarization, caspase-3/7 activation, and the emergence of sub-G1 cell populations using flow cytometry, fluorescence microscopy and quantitative real time (qRT)-PCR. These effects were compared under different oxygen concentrations.
resultsTH-302 induced DNA damage and reduced cell number in ES cells by over 60%, preferentially under hypoxic conditions, independent of the cellular p53 status. TH-302 caused cell death in up to 40% of cells and mitochondrial depolarization in up to 60% of cells. Additionally, TH-302-induced caspase-3/7 activation and increased sub-G1 cell populations predominantly under hypoxia, with the most pronounced effects occurring at 0.2% environmental oxygen compared to 1% O
conclusionThese in vitro findings suggest that TH-302 may be efficacious in ES. This provides a rationale for further in vivo investigations into the potential of TH-302 as a treatment for ES.
Indexed as
Identifiers
40515777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.